Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

BMC cancer - 9 Apr 2009

Auner Veronika, Kriegshäuser Gernot, Tong Dan, Horvat Reinhard, Reinthaller Alexander, Mustea Alexander, Zeillinger Robert

Abstract excerpt

BACKGROUND: Mutations in the KRAS gene are one of the most frequent genetic abnormalities in ovarian carcinoma. They are of renewed interest as new epidermal growth factor receptor (EGFR)-targeted therapies are being investigated for use in ovarian carcinoma. As KRAS mutations are associated with poor response and resistance to EGFR-targeting drugs, this study was conducted to obtain more information on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Codon
Share to Ovarian Neoplasms
Share to Ovary

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 19358724
DOI: 10.1186/1471-2407-9-111
PMCID: PMC2671522

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.PMID 19358724Read ↗

Exploration of Kras Mutations and Their Potential for Being a Target Molecule in Cancer ChemotherapySemantic proximity Read ↗

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Semantic proximity Read ↗

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.Semantic proximity Read ↗

Laboratory methods for<i>KRAS</i>mutation analysisSemantic proximity Read ↗

KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.Semantic proximity Read ↗

TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.Semantic proximity Read ↗

Biochip for K-ras mutation screening in ovarian cancer.Semantic proximity Read ↗

Biochip-based detection of KRAS mutation in non-small cell lung cancer.Semantic proximity Read ↗

Multiplex detection of KRAS mutations by a matrix-assisted laser desorption/ionization-time of flight mass spectrometry assay.Semantic proximity Read ↗

Mutational Aberrations Detected in Mucinous Epithelial Ovarian Cancer of Asian Women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.